Regen BioPharma Inc (RGBP)

[Dcab]

I couldn't agree with you any more OTC. The simple fact is to bring a drug/vaccine through clinical trials is so expensive that deep pockets are needed so buyouts are very common in these situations. Moreover this stock has a large short position and what this needs next week is for the buyers to overwhelm the flippers and push the PPS to a point that triggers the shorts to cover. Notice that the L2 has thinned out over the past week. Should be an interesting week. JMO